Neurons-targeting Adenovirus Vector Construction Service
Through our comprehensive early discovery, nonclinical and commercialization services, Creative Biolabs is committed to developing the most promising viral vectors for our clients. With in-depth expertise in vector design, vector construction, as well as in vivo and in vitro studies, we can provide a series of adenovirus vector services basing on a full range of state-of-art technologies. Nowadays, we provide high-quality customized assays, with different formats, endpoints, parameters, to satisfy any specific requirement at a most competitive price.
Why Neuron-Specific Gene Delivery Remains a Critical Bottleneck?
Despite significant advances in viral vector engineering, achieving efficient and selective gene delivery to neurons remains a major challenge in both basic and translational neuroscience. Several biological and technical barriers limit the success of current approaches:
| Key Challenge | Impact on Research & Therapy | Our Solution |
|---|---|---|
| Blood-brain barrier (BBB) | Limits systemic delivery to CNS | Capsid engineering & delivery strategy optimization |
| Cellular heterogeneity | Off-target expression in glial cells | Neuron-specific targeting strategies |
| Low transduction efficiency | Weak gene expression | Tropism-modified vectors |
| Immune activation | Reduced vector persistence | PEGylation & immune shielding |
| Complex neural circuits | Difficult functional interpretation | Retrograde & tracing vectors |
Introduction of Adenovirus Vector
Adenoviruses (Ads), a member of the Adenoviridae family, are the main cause of many respiratory illnesses, including pneumonia, respiratory tract infection as well as conjunctivitis. Ads have a linear DNA genome with a length of 36000 based pairs, and the genome is responsible for encoding about 35 proteins in the process of DNA replication. In the past few years, a broad range of adenovirus serotypes have been identified, for instance, more than 57 serotypes of human Ads have been defined by using cell cultures targeting different kinds of anti-sera. Meanwhile, pilot studies have also shown that adenovirus vector is an attractive delivery system for gene transfer in non-dividing or dividing cells. A number of adenovirus vectors have been developed for treating various diseases, especially for cancers. The results in clinical trials suggest that adenovirus vector is a safe and effective gene transfer system with high viral titers. Currently, most Ad vectors have been constructed by modifying Ad2 or Ad5, for instance, the replication-defective Ad5 vector and the replication-competent Ad5 vector have been widely used for neurons-associated disease therapy.
Figure 1. Structure of adenovirus and its genome. E1–E4—early genes, L1–L5—late genes.1
Why Adenovirus? The Strategic Advantage in Neuroscience
While AAV and Lentivirus are common, the Adenovirus (Ad) remains an irreplaceable tool for specific high-demand neural applications. Understanding the biophysical differences is key to selecting the right vector for your circuit or disease model.
| Feature | Adenovirus (Ad5) | Adeno-Associated Virus (AAV) | Lentivirus (LV) |
|---|---|---|---|
| Cloning Capacity | Large (8.5 – 30 kb) | Small (<4.7 kb) | Medium (~8 kb) |
| Expression Onset | Rapid (24–48 hours) | Slow (2–4 weeks) | Moderate (1 week) |
| Genomic Integration | No (Episomal) | Low/No | Yes (Random Integration) |
| Neuronal Tropism | High (with engineering) | High (Serotype dependent) | Moderate |
| Inflammatory Profile | Moderate (Dose-dependent) | Low | Low |
What We Offer?
Creative Biolabs has developed a series of services to design and construct adenovirus vectors targeting neurons for our clients. E1A and E1B deleted adenovirus vectors are commonly used for expressing foreign transgenes in our labs. These vectors can be cultured in many kinds of cells lines, including HEK293. In addition, we have successfully transferred genes into the neurons and glial cells by using Ads. The transgene expression has been evaluated by a wide collection of assays, such as fluorescence-activated cell sorting (FACS) assay, enzyme-linked immunosorbent assay (ELISA) and real-time PCR assay. Up to now, we have established protocols to clone, infect, and test neurons-targeting adenoviral vectors to ensure their safety and efficacy in gene therapy.
01. Custom Adenoviral Vector Design & Construction
We don't just clone; we engineer. Our molecular biology team works with you to design the most effective expression cassette for neuronal tissues.
- Gene Synthesis & Subcloning: Optimized for large-cargo genes.
- Multiplexed Expression: Bi-cistronic or tri-cistronic vectors using IRES or 2A peptides to express multiple proteins (e.g., a therapeutic gene + a fluorescent reporter) from a single promoter.
- Conditional Expression: Construction of DIO (Double-floxed Inverted Orientation) or FLEx vectors for cell-type-specific expression in Cre-driver transgenic mice.
02. Neuro-Specific Capsid Engineering (Tropism Modification)
Standard Adenovirus (Ad5) often shows poor affinity for mature neurons. We offer specialized "cloaking and targeting" modifications:
- Fiber-Knob Chimerism: Swapping Ad5 fiber with Ad11, Ad35, or Ad37 fibers to bypass CAR-dependency and target sialic acid or CD46 receptors prevalent in the CNS.
- Peptide Display: Insertion of neuron-binding motifs (e.g., Tetanus Toxin Fragment C or RVG peptides) into the fiber protein to enhance uptake by distal axons.
- PEGylation & Shielding: Chemical modification services to reduce pre-existing neutralizing antibody (nAb) interference for systemic administration.
03. Precision Packaging & Purification
The brain is highly sensitive to impurities. Our purification process is specifically designed to minimize neuroinflammation and cytotoxicity.
- High-Titer Scaling: Standard yields at 10¹² VP/mL, with ultra-high concentration options up to 10¹³ VP/mL for micro-injection into small nuclei.
- Triple-Step Purification: Combining Ion Exchange Chromatography (IEC) with CsCl ultracentrifugation to achieve > 98% purity.
- Empty Capsid Removal: Advanced gradient separation to ensure a high full-to-empty ratio, reducing unnecessary antigenic load.
04. Specialized Retrograde & Anterograde Ad-Vectors
Mapping the connectome requires specialized transport kinetics.
- Retro-Ad Engineering: Modified vectors that efficiently enter at the synapse and travel back to the soma, ideal for labeling projection neurons.
- Anterograde Trans-synaptic Tracing: Specialized Ad-variants designed to cross synapses, allowing for the functional mapping of first-order and second-order neuronal connections.
05. In Vitro & In Vivo Validation Services
Don't wait for your animal results to find out if a construct works. We offer pre-shipment validation:
- Primary Neuron Transduction Assay: Testing the vector on rat/mouse primary hippocampal or cortical neurons to confirm expression and toxicity profiles.
- iPSC-derived Human Neuron Testing: Validating targeting efficiency in human-derived cellular models.
- Biodistribution Profiling: Using qPCR to quantify viral genome copies across different brain regions and peripheral organs following injection.
What You'll Receive
| Delivery | Description |
|---|---|
| Customized Adenoviral Vector | Fully engineered neuron-targeting vector |
| High-Titer Viral Stock | ≥10¹²–10¹³ VP/mL ready for experiments |
| Validation Data Package | Expression, tropism, and safety validation |
| Quality Control Report | Purity, endotoxin, sterility, genome integrity |
| Technical Support | Experimental design and optimization guidance |
Applications of Our Services
Our neuron-targeting adenoviral vectors are widely used in:
- Neurodegenerative disease research (Alzheimer's, Parkinson's)
- Neural circuit mapping and connectomics
- CNS gene therapy development
- Optogenetics and chemogenetics
- Functional genomics in neurons
Why Partner with Us?
We combine deep expertise in viral vector engineering with a strong understanding of CNS biology to deliver high-quality, reliable solutions.
- Proven ability to achieve high-efficiency neuronal transduction
- Advanced targeting strategies for improved specificity
- Integrated in vitro and in vivo validation capabilities
- Rapid project turnaround with flexible customization
- Extensive experience in CNS-focused gene delivery projects
Our services are designed not only to meet technical requirements, but also to accelerate your research outcomes and reduce experimental risk.
Customer Reviews
Frequently Asked Questions
Q1: How do you improve neuron specificity in adenoviral vectors?
A: We employ a combination of capsid engineering and transcriptional targeting strategies to enhance neuron specificity. This includes fiber-knob modification, peptide ligand insertion (e.g., RVG or Tet1), and the use of neuron-specific promoters such as synapsin. By integrating both entry-level targeting and expression-level control, we significantly reduce off-target transduction in glial cells while improving neuronal expression efficiency.
Q2: Can your vectors be used for in vivo CNS delivery?
A: Yes. Our neuron-targeting adenoviral vectors are optimized for both in vitro and in vivo applications, including direct intracranial injection, stereotaxic delivery, and selected systemic strategies. We also offer biodistribution analysis and validation services to help you evaluate vector performance across different brain regions and ensure reliable experimental outcomes.
Q3: What types of adenoviral modifications or serotypes do you support?
A: We support a wide range of adenoviral platforms, including Ad5-based systems and chimeric serotypes such as Ad11 and Ad35. In addition, we offer custom capsid engineering solutions, including receptor retargeting, peptide display, and immune shielding modifications. All designs can be tailored based on your specific neuronal targets and experimental goals.
Q4: What is the typical turnaround time for a project?
A: The standard timeline ranges from 4 to 8 weeks, depending on the complexity of the vector design and validation requirements. For projects involving advanced capsid engineering or in vivo validation, timelines may be slightly extended. We also offer flexible project planning and expedited options to support urgent research needs.
Q5: Do you provide validation data before delivery?
A: Yes. We provide a comprehensive validation data package prior to delivery, which may include transduction efficiency, gene expression analysis (qPCR, ELISA, FACS), and cytotoxicity assessment. Optional services such as primary neuron testing or iPSC-derived neuron validation are also available to ensure your vector performs as expected in relevant biological systems.
Start Your Project Today
As a global contract research organization, Creative Biolabs works on a wide range of viral vector discovery and development services for various disease types. We utilize unrivaled, proprietary vector design, study data, product candidate, advanced project life-cycle management, as well as real-time data to ensure the ideal outcomes. If you are interested in our services, please feel free to contact us for closer communication to learn how we can be involved in your project. Separate services or integrated end-to-end solutions are all welcomed.
Reference
- Muravyeva A, Smirnikhina S. Adenoviral vectors for gene therapy of hereditary diseases. Biology, 2024, 13(12): 1052. https://doi.org/10.3390/biology13121052 Distributed under Open Access license CC BY 4.0, without modification.
